Recruiting INTERVENTIONAL NCT06948435

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)

Sponsor: Eli Lilly and Company

Conditions Hypertension Overweight or Obesity

Interventions Orforglipron Placebo

Updated 12 times since 2025 Last updated: Apr 16, 2026 Started: Apr 30, 2025 Primary completion: Sep 1, 2027 Completion: Sep 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Hypertension and Overweight or Obesity and is currently actively recruiting participants. Eli Lilly and Company leads this study, which shows 12 recorded versions since 2025 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

12 versions recorded

Apr 18, 2026 — Present [daily]

Recruiting

Phase: PHASE3 → None
Mar 2026 — Apr 2026 [monthly]

Recruiting PHASE3
Feb 2026 — Mar 2026 [monthly]

Recruiting PHASE3
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE3
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE3

▶ Show 7 earlier versions

Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE3
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE3
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE3
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE3
Jul 2025 — Aug 2025 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jun 2025 — Jul 2025 [monthly]

Not Yet Recruiting PHASE3
May 2025 — Jun 2025 [monthly]

Not Yet Recruiting PHASE3

First recorded

Apr 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , A Coruña, Spain , Athens, Greece , Athens, Greece , Bad Homburg, Germany , Baltimore, United States , Bangalore, India , Barcelona, Spain , Beijing, China , Berlin, Germany and 89 more locations